In fact, pharmacological inhibition of DYRK1A reduces Aβ and tau pathology and improves AD-related cognitive impairments in mouse models of AD, delaying the onset of both Aβ plaques and tau-containing neurofibrillary tangles (NFTs) (40). This evidence concerns the gene MAPT and Cognitive impairment.